Differential responses of pulmonary vascular cells from PAH patients and controls to TNFα and the effect of the BET inhibitor JQ1.
Bromodomain and extra‐terminal proteins
Human pulmonary artery smooth muscle cells
Human pulmonary microvascular endothelial cells
Inflammation
Pulmonary arterial hypertension
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
29 Jul 2023
29 Jul 2023
Historique:
received:
07
02
2023
accepted:
23
07
2023
medline:
31
7
2023
pubmed:
30
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
Pulmonary arterial hypertension (PAH) encompasses a group of diseases characterized by raised pulmonary vascular resistance, resulting from vascular remodelling and inflammation. Bromodomain and extra-terminal (BET) proteins are required for the expression of a subset of NF-κB-induced inflammatory genes which can be inhibited by the BET mimic JQ1+. We hypothesised that JQ+ would supress TNFα-driven inflammatory responses in human pulmonary vascular cells from PAH patients. Immunohistochemical staining of human peripheral lung tissue (N = 14 PAH and N = 12 non-PAH) was performed for the BET proteins BRD2 and 4. Human pulmonary microvascular endothelial cells (HPMEC) and pulmonary artery smooth muscle cells (HPASMC) from PAH patients (N = 4) and non-PAH controls (N = 4) were stimulated with TNFα in presence or absence of JQ1+ or its inactive isomer JQ1-. IL-6 and -8 mRNA was measured by RT-qPCR and protein levels by ELISA. Chromatin immunoprecipitation analysis was performed using EZ-ChIP™ and NF-κB p65 activation determined using a TransAm kit. MTT assay was used to measure cell viability. Nuclear staining of BRD2 and BRD4 was significantly (p < 0.0001) increased in the lung vascular endothelial and smooth muscle cells from PAH patients compared to controls with normal lung function. TNFα-driven IL-6 release from both HPMECs and HPASMCs was greater in PAH cells than control cells. Levels of CXCL8/IL-8 protein release was higher in PAH HPASMCs than in control cells with similar release observed in HPMECs. TNFα-induced recruitment of activated NF-κB p65 to the IL-6 and CXCL8/IL-8 promoters were similar in both cell types and between subject groups. JQ1+ suppressed TNFα-induced IL-6 and CXCL8/IL-8 release and mRNA expression to a comparable extent in control and PAH HPMECs and HPASMCs. JQ1 had a greater efficacy on IL-6 release in HPMEC and on CXCL8/IL-8 release in HPASMC. BET inhibition decreases TNFα driven inflammation in primary pulmonary vascular cells. The anti-inflammatory actions of JQ1 suggests distinct cell-specific regulatory control of these genes. BET proteins could be a target for future therapies for PAH.
Sections du résumé
BACKGROUND
BACKGROUND
Pulmonary arterial hypertension (PAH) encompasses a group of diseases characterized by raised pulmonary vascular resistance, resulting from vascular remodelling and inflammation. Bromodomain and extra-terminal (BET) proteins are required for the expression of a subset of NF-κB-induced inflammatory genes which can be inhibited by the BET mimic JQ1+. We hypothesised that JQ+ would supress TNFα-driven inflammatory responses in human pulmonary vascular cells from PAH patients.
METHODS
METHODS
Immunohistochemical staining of human peripheral lung tissue (N = 14 PAH and N = 12 non-PAH) was performed for the BET proteins BRD2 and 4. Human pulmonary microvascular endothelial cells (HPMEC) and pulmonary artery smooth muscle cells (HPASMC) from PAH patients (N = 4) and non-PAH controls (N = 4) were stimulated with TNFα in presence or absence of JQ1+ or its inactive isomer JQ1-. IL-6 and -8 mRNA was measured by RT-qPCR and protein levels by ELISA. Chromatin immunoprecipitation analysis was performed using EZ-ChIP™ and NF-κB p65 activation determined using a TransAm kit. MTT assay was used to measure cell viability.
RESULTS
RESULTS
Nuclear staining of BRD2 and BRD4 was significantly (p < 0.0001) increased in the lung vascular endothelial and smooth muscle cells from PAH patients compared to controls with normal lung function. TNFα-driven IL-6 release from both HPMECs and HPASMCs was greater in PAH cells than control cells. Levels of CXCL8/IL-8 protein release was higher in PAH HPASMCs than in control cells with similar release observed in HPMECs. TNFα-induced recruitment of activated NF-κB p65 to the IL-6 and CXCL8/IL-8 promoters were similar in both cell types and between subject groups. JQ1+ suppressed TNFα-induced IL-6 and CXCL8/IL-8 release and mRNA expression to a comparable extent in control and PAH HPMECs and HPASMCs. JQ1 had a greater efficacy on IL-6 release in HPMEC and on CXCL8/IL-8 release in HPASMC.
CONCLUSION
CONCLUSIONS
BET inhibition decreases TNFα driven inflammation in primary pulmonary vascular cells. The anti-inflammatory actions of JQ1 suggests distinct cell-specific regulatory control of these genes. BET proteins could be a target for future therapies for PAH.
Identifiants
pubmed: 37516840
doi: 10.1186/s12931-023-02499-y
pii: 10.1186/s12931-023-02499-y
pmc: PMC10386603
doi:
Substances chimiques
Tumor Necrosis Factor-alpha
0
Interleukin-8
0
(+)-JQ1 compound
0
Interleukin-6
0
NF-kappa B
0
Nuclear Proteins
0
Transcription Factors
0
BRD4 protein, human
0
Cell Cycle Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
193Subventions
Organisme : British Heart Foundation
ID : PG/14/27/30679
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/14/27/30679
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/14/27/30679
Pays : United Kingdom
Informations de copyright
© 2023. The Author(s).
Références
Int J Mol Sci. 2018 Jul 30;19(8):
pubmed: 30061518
Can J Cardiol. 2015 Apr;31(4):407-15
pubmed: 25630876
Nat Protoc. 2017 Apr;12(4):697-731
pubmed: 28253237
Front Immunol. 2021 Feb 26;12:626255
pubmed: 33717143
Am J Respir Crit Care Med. 2022 Jun 1;205(11):1357-1360
pubmed: 35289736
Am J Physiol Lung Cell Mol Physiol. 2021 May 1;320(5):L726-L738
pubmed: 33565360
Am J Respir Crit Care Med. 2019 Oct 1;200(7):910-920
pubmed: 31042405
Physiology (Bethesda). 2009 Apr;24:97-106
pubmed: 19364912
Eur Respir J. 2023 Jan 6;61(1):
pubmed: 36028254
Cell Signal. 2019 Sep;61:20-29
pubmed: 31075399
Nature. 2010 Dec 23;468(7327):1119-23
pubmed: 21068722
PLoS One. 2013 Oct 04;8(10):e75415
pubmed: 24124488
N Engl J Med. 2021 Dec 16;385(25):2361-2376
pubmed: 34910865
Mol Cell. 2019 Feb 7;73(3):621-638.e17
pubmed: 30554943
Sci Adv. 2021 Oct 22;7(43):eabh3794
pubmed: 34669463
Circulation. 2014 Apr 29;129(17):1770-80
pubmed: 24503951
Nat Rev Cancer. 2012 Jun 22;12(7):465-77
pubmed: 22722403
Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):11365-70
pubmed: 25049379
Oncogene. 2014 May 1;33(18):2395-404
pubmed: 23686307
Cell Signal. 2010 Sep;22(9):1282-90
pubmed: 20363318
Orphanet J Rare Dis. 2013 Jul 06;8:97
pubmed: 23829793
Curr Opin Drug Discov Devel. 2009 Sep;12(5):659-65
pubmed: 19736624
Epigenetics Chromatin. 2019 Jul 2;12(1):39
pubmed: 31266503
Cell. 2002 Feb 22;108(4):489-500
pubmed: 11909520
EMBO Rep. 2002 Mar;3(3):224-9
pubmed: 11882541
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545968
J Immunol. 2021 Jan 15;206(2):422-431
pubmed: 33288543
Annu Rev Biochem. 2007;76:75-100
pubmed: 17362198
J Biol Chem. 2013 Dec 13;288(50):36094-105
pubmed: 24189064
Circulation. 2010 Aug 31;122(9):920-7
pubmed: 20713898
Respirology. 2017 Jan;22(1):157-164
pubmed: 27539364
Cell Res. 2011 Mar;21(3):381-95
pubmed: 21321607
Br J Pharmacol. 2017 Jan;174(1):101-115
pubmed: 27774624
Arterioscler Thromb Vasc Biol. 2017 Aug;37(8):1513-1523
pubmed: 28473439
FEBS Lett. 2012 Aug 14;586(17):2692-704
pubmed: 22710155
Front Cardiovasc Med. 2022 Jul 14;9:924873
pubmed: 35911521
JAMA. 2020 Apr 28;323(16):1565-1573
pubmed: 32219359
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Proteomics. 2019 Aug 15;205:103415
pubmed: 31195152
Mol Cell Biol. 2009 Mar;29(5):1375-87
pubmed: 19103749
Biochem Cell Biol. 2015 Apr;93(2):149-57
pubmed: 25707943
Chest. 2015 Oct;148(4):1043-54
pubmed: 26066077
Nature. 2014 Dec 11;516(7530):272-5
pubmed: 25252976
Pulm Circ. 2021 Mar 2;11(1):2045894021996190
pubmed: 34408849
Pulm Pharmacol Ther. 2009 Aug;22(4):318-25
pubmed: 19489131
Rheumatology (Oxford). 2016 Jan;55(1):173-84
pubmed: 26324948
Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):19754-9
pubmed: 24248379
Circ Res. 2015 Aug 28;117(6):525-35
pubmed: 26224795
Eur Respir J. 2006 Jul;28(1):219-42
pubmed: 16816350
J Biol Chem. 2012 Aug 17;287(34):28840-51
pubmed: 22645123
J Cell Mol Med. 2021 May;25(10):4732-4743
pubmed: 33755319